Osaka: Japanese researchers succeeded in making the world's smallest intravenously injectable super
apatite gene delivery reagents at just 10nm, while also succeeding in
accumulating nucleic acids in solid tumors with considerable efficiency. RNAi technology for solid tumors, especially in systemic administration, still faces numerous hurdles. In addition to stability in the blood flow, an ideal system requires (i) quick delivery of siRNA to the tumor cells since siRNA easily gets damage, ii) sufficient cellular uptake, iii) radical endosomal escape, permitting a rapid cytoplasm diffusion. The CA system surmounted every hurdle. Owing to its distinctly innovative delivery efficiency and anti-tumor activity in vivo, we designated the sonicated small nanoparticle as super carbonate apatite. This simple, inexpensive, and highly efficient in vivo delivery system may open a new avenue in nucleotide medicine.
